Langues

Publications

Neurolixis is a science-driven company and places high priority on characterizing its drug development candidates (NLX-112 and NLX-101) in rigorously-conducted pharmacological studies. The results from these studies are reported in reputable international peer-reviewed neuroscience and pharmacology journals.
To view nearly 50 articles on NLX-112 and NLX-101 see the complete list of publications on PubMed (from US National Library of Medicine)

For abstracts of key publications (and some free PDFs of the full articles) see the links below.

Note: NLX-112 was previously known as F13640 (befiradol) and NLX-101 was previously known as F15599.

 

Selected Publications on NLX-112:

Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist

Newman-Tancredi A, Martel J-C, Cosi C, Heusler P, Lestienne F, Varney MA, Cussac D.
Journal of Pharmacy and Pharmacology, 2017 June 14. DOI: 10.1111/jphp.12762

 

The novel 5-HT1A receptor agonist, NLX-112, reduces L-DOPA-induced abnormal involuntary movements in rat: a chronic administration study with microdialysis measurements.

McCreary AC, Varney MA, Newman-Tancredi A
Neuropharmacology. 2016 Jan 8. pii: S0028-3908(16)30013-2. doi: 10.1016/j.neuropharm.2016.01.013.

 

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A
Exp Neurol. 2015 May 30. doi: 10.1016/j.expneurol.2015.05.021

 

In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and post-synaptic 5-HT1A receptors in the rat.

Lladò-Pelfort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P.
Psychopharmacology (Berl). 2012 May;221(2):261-72. Epub 2011 Dec 3.

 

Dual hyperalgesic and analgesic effects of the high-efficacy 5-HT1A agonist F13640: relationship with receptor occupancy and kinetic parameters.

Bardin L, Assié MB, Pélissou M, Royer-Urios I, Newman-Tancredi A, Ribet JP, Sautel F, Koek W, Colpaert FC.
J Pharmacol Exp Ther. 2005 Mar;312(3):1034-42. Epub 2004 Nov 4.    Free PDF  pdf_symbol

 

Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain

Sałat K, Kołaczkowski M, Furgała A, Rojek A, Śniecikowska J, Varney MA, Newman-Tancredi A
Neuropharmacology. 2017 Jul 24;125:181-188. doi: 10.1016/j.neuropharm.2017.07.022.

 

Selected Publications on NLX-101:

Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study (free PDF).

Becker G, Bolbos R, Costes N, Redouté J, Newman-Tancredi A, Zimmer L
Sci Rep. 2016 May 23;6:26633. doi: 10.1038/srep26633.    Free PDF  pdf_symbol

 

Pinpointing brain stem mechanisms responsible for autonomic dysfunction in Rett syndrome: therapeutic perspectives for 5-HT1A agonists

Ana P. Abdala, John Bissonnette, Adrian Newman-Tancredi,
Frontiers in Physiology 5: 205, 2014. doi: 10.3389/fphys.2014.00205   Free PDF  pdf_symbol

 

A selective 5-HT1A receptor agonist improves respiration in a mouse model of Rett syndrome.

Levitt ES, Hunnicutt BJ, Knopp SJ, Williams JT, Bissonnette JM.
J Appl Physiol (1985). 2013 Dec;115(11):1626-33. Epub 2013 Oct 3.

 

Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. 

Newman-Tancredi A, Martel JC, Assié MB, Buritova J, Lauressergues E, Cosi C, Heusler P, BruinsSlot L, Colpaert F, Vacher B, Cussac D.
Br J Pharmacol. 2009 Jan;156(2):338-53. Epub 2009 Jan 12.    Free PDF  pdf_symbol

 

Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors.

Lladó-Pelfort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P.
Br J Pharmacol. 2010 Aug;160(8):1929-40.     Free PDF  pdf_symbol

 

F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists.

Depoortère R, Auclair AL, Bardin L, Colpaert FC, Vacher B, Newman-Tancredi A.,
Eur Neuropsychopharmacol. 2010 Sep;20(9):641-54.

 

Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders.

Newman-Tancredi A,
Neuropsychiatry, April 2011, Vol. 1, No. 2, Pages 149-164.